Search
for
Sort by
Research 241–270 of 785
- Skin Pigmentation Types, Causes and Treatment—A Review
- A Comprehensive Review on Skin Pigmentation-Types, Causes, and Treatment
- Alopecia Areata: An Updated Review for 2023
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
- Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Stem cell-based therapies for alopecia areata: a narrative review
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Targeted immunotherapy for hair regrowth and regeneration
- Predominant expression of interleukin (IL)‐17 in chronic alopecia areata compared to IFN‐γ in pathogenic Th17 cells, tissue‐resident memory T cells and natural killer cells
- Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways
- Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Ritlecitinib in severe alopecia areata: a profile of its use
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Effects of the RV3466F lotion on female telogen effluvium: Results from a 16 week, multi-centric, controlled, randomized trial
- New therapies for alopecia areata
- Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Efficacy of tofacitinib in treatment of alopecia universalis in two patients
- Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
- Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
- Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response